The Path Forward: A Journey into Cell and Gene Therapy Through DBT and BIRAC’s Webinar
In an era where medical needs are exploding, innovative treatments stand as a beacon of hope. This webinar, hosted by the Department of Biotechnology (DBT) and Biodiversity Information Research and Analysis (BIRAC), highlighted the transformative potential of Cell and Gene Therapy under the Precision Biotherapeutics Policy. The session underscored DBT’s role in fostering sustainable green growth and high-performance biomanufacturing, emphasizing the critical nature of cell therapies for treating diseases like cancer and rare conditions.
Dr. Alka Sharma introduced the policy’s vision, stressing its importance as a catalyst for global leadership. She underscored how this sector is essential at a time of rising medical needs, positioning it globally and nationally. Dr. Kamakshi Chaithri broke down the steps DBT has taken under BioE3 Policy, highlighting advancements in gene editing technologies like CRISPR-Cas9. Her insights provided a roadmap for addressing manufacturing challenges, ensuring access and affordability.
Dr. Debojyoti Chakraborty’s discussions on CRISPR techniques deepened understanding of disease treatments such as sickle cell. His focus on scale-up and regulatory hurdles highlighted the need for improved accessibility. Dr. Anil Kamat’s emphasis on CAR-T therapy by Immuneel Therapeutics offered practical insights, addressing challenges in scaling production and ensuring quality.
The webinar concluded with a vibrant Q&A session, offering readers actionable advice to enhance their biomanufacturing strategies. The event underscored how these therapies are making significant contributions in medical treatment, inspiring continued innovation and collaboration among experts at DBT and BIRAC.
Conclusion: The 12th Webinar by DBT and BIRAC highlighted the pivotal role of Cell and Gene Therapy in addressing life-threatening diseases. Through expert insights and practical advice, it emphasized the need for strategic interventions and enhanced accessibility, positioning this sector as a cornerstone of global biotechnology.